(Measles [strain Edmonstons-Zagreb] + rubella [strain RA-27]) vaccine is under clinical development by Micron Biomedical and currently in Phase II for Rubella (German Measles). According to GlobalData, Phase II drugs for Rubella (German Measles) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the (Measles [strain Edmonstons-Zagreb] + rubella [strain RA-27]) vaccine LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Measles [strain Edmonstons-Zagreb] + rubella [strain RA-27]) vaccine overview
Vaccine candidate is under development for the prevention of measles and rubella. It is a live attenuated vaccine administered by transdermal route. The therapeutic candidate is developed based on microneedle patch technology.
Micron Biomedical overview
Micron Biomedical (Micron) is a biopharmaceutical company that is engaged in research and development of pharmaceutical products by using microneedle patch technology. The company is headquartered in Atlanta, Georgia, the US.
For a complete picture of (Measles [strain Edmonstons-Zagreb] + rubella [strain RA-27]) vaccine’s drug-specific PTSR and LoA scores, buy the report here.